Evidence map›Paper›PMID 34153511›Full record

ArticleActa biomaterialia2021

High-throughput microfluidic 3D biomimetic model enabling quantitative description of the human breast tumor microenvironment.

Ilana Berger Fridman, James Kostas, Michal Gregus, Somak Ray, Matthew R Sullivan, Alexander R Ivanov, Smadar Cohen, Tania Konry

Open access · greenAbstract read
In one paragraph

Article in Acta biomaterialia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Immune organoid for cancer immunotherapy.Acta pharmaceutica Sinica. B · 2025
    Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Ilana Berger FridmanDepartment of Pharmaceutical Sciences, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA; Avram and Stella Goldstein-Goren Department of Biotechnology Engineering and Regenerative Medicine and Stem Cell Center, Ben-Gurion University of the Negev, POB 653, Beer-Sheva 84105, Israel. Electronic address: bergeri@post.bgu.ac.il.
James KostasDepartment of Chemistry and Chemical Biology, Barnett Institute of Chemical and Biological Analysis, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA. Electronic address: kostas.j@northeastern.edu.
Michal GregusDepartment of Chemistry and Chemical Biology, Barnett Institute of Chemical and Biological Analysis, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA. Electronic address: m.gregus@northeastern.edu.
Somak RayDepartment of Chemistry and Chemical Biology, Barnett Institute of Chemical and Biological Analysis, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA. Electronic address: s.ray@northeastern.edu.
Matthew R SullivanDepartment of Pharmaceutical Sciences, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA. Electronic address: sullivan.mat@husky.neu.edu.
Alexander R IvanovDepartment of Chemistry and Chemical Biology, Barnett Institute of Chemical and Biological Analysis, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA. Electronic address: a.ivanov@northeastern.edu.
Smadar CohenAvram and Stella Goldstein-Goren Department of Biotechnology Engineering and Regenerative Medicine and Stem Cell Center, Ben-Gurion University of the Negev, POB 653, Beer-Sheva 84105, Israel. Electronic address: scohen@bgu.ac.il.
Tania KonryDepartment of Pharmaceutical Sciences, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA. Electronic address: t.konry@northeastern.edu.
Northeastern University · USBen-Gurion University of the Negev · IL

Funding

Effect of methodological and biological variability on molecular profiling of extracellular vesicles in cancer detectionR01CA218500 · NCI · NORTHEASTERN UNIVERSITY · PI GHIRAN, IONITA CALIN, IVANOV, ALEXANDER R. · 2018 to 2022
$4.0M
Robust ultra-high sensitivity proteomic technologies for limited samplesR35GM136421 · NIGMS · NORTHEASTERN UNIVERSITY · PI Alexander R. Ivanov · 2020 to 2026
$3.4M
Deep Proteomic Profiling of Rare CellsR01GM120272 · NIGMS · NORTHEASTERN UNIVERSITY · PI IVANOV, ALEXANDER R. · 2016 to 2019
$1.5M
Determining treatment sensitivity in B cell lymphoma by novel microfluidics-based NK cell immunogenicity platformR33CA223908 · NCI · NORTHEASTERN UNIVERSITY · PI EVENS, ANDREW M, HUANG, TONY JUN · 2018 to 2020
$1.2M
An integrated acoustofluidic droplet-sorting platform for classification of lymphocyte activity and functional phenotyping at single cell levelR01GM127714 · NIGMS · NORTHEASTERN UNIVERSITY · PI KONRY, TANIA TALI · 2018 to 2021
$1.2M
NCI NIH HHS R01 CA218500NCI NIH HHS R33 CA223908NIGMS NIH HHS R01 GM120272NIGMS NIH HHS R01 GM127714NIGMS NIH HHS R35 GM136421
6 · The paper itself

Abstract

Cancer is driven by both genetic aberrations in the tumor cells and fundamental changes in the tumor microenvironment (TME). These changes offer potential targets for novel therapeutics, yet lack of in vitro 3D models recapitulating this complex microenvironment impedes such progress. Here, we generated several tumor-stroma scaffolds reflecting the dynamic in vivo breast TME, using a high throughput microfluidic system. Alginate (Alg) or alginate-alginate sulfate (Alg/Alg-S) hydrogels were used as ECM-mimics, enabling the encapsulation and culture of tumor cells, fibroblasts and immune cells (macrophages and T cells, of the innate and adaptive immune systems, respectively). Specifically, Alg/Alg-S was shown capable of capturing and presenting growth factors and cytokines with binding affinity that is comparable to heparin. Viability and cytotoxicity were shown to strongly correlate with the dynamics of cellular milieu, as well as hydrogel type. Using on-chip immunofluorescence, production of reactive oxygen species and apoptosis were imaged and quantitatively analyzed. We then show how macrophages in our microfluidic system were shifted from a proinflammatory to an immunosuppressive phenotype when encapsulated in Alg/Alg-S, reflecting in vivo TME dynamics. LC-MS proteomic profiling of tumor cells sorted from the TME scaffolds revealed upregulation of proteins involved in cell-cell interactions and immunomodulation in Alg/Alg-S scaffolds, correlating with in vivo findings and demonstrating the appropriateness of Alg/Alg-S as an ECM biomimetic. Finally, we show the formation of large tumor-derived vesicles, formed exclusively in Alg/Alg-S scaffolds. Altogether, our system offers a robust platform for quantitative description of the breast TME that successfully recapitulates in vivo patterns. STATEMENT OF SIGNIFICANCE: Cancer progression is driven by profound changes in both tumor cells and surrounding stroma. Here, we present a high throughput microfluidic system for the generation and analysis of dynamic tumor-stroma scaffolds, that mimic the complex in vivo TME cell proportions and compositions, constructing robust in vitro models for the study of the TME. Utilizing Alg/Alg-S as a bioinspired ECM, mimicking heparin's in vivo capabilities of capturing and presenting signaling molecules, we show how Alg/Alg-S induces complex in vivo-like responses in our models. Alg/Alg-S is shown here to promote dynamic protein expression patterns, that can serve as potential therapeutic targets for breast cancer treatment. Formation of large tumor-derived vesicles, observed exclusively in the Alg/Alg-S scaffolds suggests a mechanism for tumor survival.

Indexed as

Breast NeoplasmsTumor MicroenvironmentBiomimeticsFemaleHumansMicrofluidicsProteomics3D disease modelsBiomaterialsBreast cancermicrofluidicsProteomic profilingTumor microenvironment

Identifiers

PMID34153511
PMCPMC8434998
OpenAlexW3176360083

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.